-To determine the antitumor activity of SAR444245 in combination with cemiplimab.
To determine the recommended phase 2 dose and to assess the safety profile of SAR444245
when combined with cemiplimab
To assess other indicators of antitumor activity
To assess the concentrations of SAR444245 when given in combination with cemiplimab
To assess the immunogenicity of SAR444245
To assess active concentrations of cemiplimab when given in combination with SAR444245
The duration of the study for an individual patient will start from the signature of the main
informed consent and include a screening period of up to 28 days, a treatment period [max 35
cycles or until PD], an end-of-treatment visit 30 days + 7 days following the last
administration of study drug (or until the patient receives another anticancer therapy,
whichever is earlier), and a follow-up visit 3 months after treatment discontinuation and
every 3 months following, until disease progression, or initiation of another antitumor
treatment, or final cohort cut-off, whichever is earlier
Malignant Melanoma, Squamous Cell Carcinoma of Skin
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.